Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Nov;81(5):790–795. doi: 10.1038/sj.bjc.6690765

Suppression of the c-erbB-2 gene product decreases transformation abilities but not the proliferation and secretion of proteases of SK-OV-3 ovarian cancer cells

K Wiechen 1, S Karaaslan 1, A Turzynski 1, M Dietel 1
PMCID: PMC2374312  PMID: 10555747

Abstract

The overexpression of the c-erbB-2 oncogene product has been reported in approximately 20–30% of human ovarian cancers and has been correlated with a poor prognosis in ovarian cancer patients. To investigate the function of p185c-erbB-2 in human ovarian cancer cells, a c-erbB-2-specific single-chain antibody (scFv-5R) was expressed in the c-erbB-2-overexpressing SK-OV-3 cell line using a retroviral expression vector. Eight individual clones expressing the single-chain antibody were isolated. These clones have a prominent retention of the cell surface p185c-erbB-2. In this study we compared the proliferation rate, the anchorage-independent growth, the secretion of matrix metalloproteases and of the urokinase-type plasminogen activator. The clones expressing the c-erbB-2 single-chain antibody, the control cells harbouring the empty vector and the parental SK-OV-3 cells they all had similar proliferation rates in the presence of 10% serum and secreted similar amounts of matrix metalloproteases and of the urokinase-type plasminogen activator. However, the expression of the c-erbB-2 oncogene product offers a strong growth advantage under serum-reduced conditions with 1% serum. In contrast to the parental SK-OV-3 and empty vector control cells, the scFv-5R-expressing clones were not able to grow anchorage-independently. These findings suggest that c-erbB-2 enhances transformation abilities of SK-OV-3 ovarian cancer cells without affecting the secretion of proteases and the proliferation of SK-OV-3 ovarian cancer cells in the presence of high concentrations of serum. © 1999 Cancer Research Campaign

Keywords: c-erbB-2 oncogene, ovarian cancer, single-chain antibody, proteases, cell transformation

Full Text

The Full Text of this article is available as a PDF (103.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beerli R. R., Graus-Porta D., Woods-Cook K., Chen X., Yarden Y., Hynes N. E. Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol Cell Biol. 1995 Dec;15(12):6496–6505. doi: 10.1128/mcb.15.12.6496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Berchuck A., Kamel A., Whitaker R., Kerns B., Olt G., Kinney R., Soper J. T., Dodge R., Clarke-Pearson D. L., Marks P. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990 Jul 1;50(13):4087–4091. [PubMed] [Google Scholar]
  3. Chambers S. K., Gertz R. E., Jr, Ivins C. M., Kacinski B. M. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer. Cancer. 1995 Apr 1;75(7):1627–1633. doi: 10.1002/1097-0142(19950401)75:7<1627::aid-cncr2820750712>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  4. Deshane J., Cabrera G., Grim J. E., Siegal G. P., Pike J., Alvarez R. D., Curiel D. T. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody. Gynecol Oncol. 1995 Oct;59(1):8–14. doi: 10.1006/gyno.1995.1260. [DOI] [PubMed] [Google Scholar]
  5. Deshane J., Grim J., Loechel S., Siegal G. P., Alvarez R. D., Curiel D. T. Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis. Cancer Gene Ther. 1996 Mar-Apr;3(2):89–98. [PubMed] [Google Scholar]
  6. Deshane J., Siegal G. P., Alvarez R. D., Wang M. H., Feng M., Cabrera G., Liu T., Kay M., Curiel D. T. Targeted tumor killing via an intracellular antibody against erbB-2. J Clin Invest. 1995 Dec;96(6):2980–2989. doi: 10.1172/JCI118370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fukazawa H., Mizuno S., Uehara Y. A microplate assay for quantitation of anchorage-independent growth of transformed cells. Anal Biochem. 1995 Jun 10;228(1):83–90. doi: 10.1006/abio.1995.1318. [DOI] [PubMed] [Google Scholar]
  8. Giani C., Casalini P., Pupa S. M., De Vecchi R., Ardini E., Colnaghi M. I., Giordano A., Ménard S. Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation. Oncogene. 1998 Jul 30;17(4):425–432. doi: 10.1038/sj.onc.1201954. [DOI] [PubMed] [Google Scholar]
  9. Graus-Porta D., Beerli R. R., Daly J. M., Hynes N. E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997 Apr 1;16(7):1647–1655. doi: 10.1093/emboj/16.7.1647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Graus-Porta D., Beerli R. R., Hynes N. E. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol. 1995 Mar;15(3):1182–1191. doi: 10.1128/mcb.15.3.1182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gum R., Wang S. W., Lengyel E., Yu D., Hung M. C., Juarez J., Boyd D. Up-regulation of urokinase-type plasminogen activator expression by the HER2/neu proto-oncogene. Anticancer Res. 1995 Jul-Aug;15(4):1167–1172. [PubMed] [Google Scholar]
  12. Hudziak R. M., Schlessinger J., Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A. 1987 Oct;84(20):7159–7163. doi: 10.1073/pnas.84.20.7159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kraus M. H., Issing W., Miki T., Popescu N. C., Aaronson S. A. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci U S A. 1989 Dec;86(23):9193–9197. doi: 10.1073/pnas.86.23.9193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Meden H., Marx D., Rath W., Kron M., Fattahi-Meibodi A., Hinney B., Kuhn W., Schauer A. Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol. 1994 Jan;13(1):45–53. doi: 10.1097/00004347-199401000-00006. [DOI] [PubMed] [Google Scholar]
  15. Noguchi M., Murakami M., Bennett W., Lupu R., Hui F., Jr, Harris C. C., Gerwin B. I. Biological consequences of overexpression of a transfected c-erbB-2 gene in immortalized human bronchial epithelial cells. Cancer Res. 1993 May 1;53(9):2035–2043. [PubMed] [Google Scholar]
  16. Pear W. S., Nolan G. P., Scott M. L., Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8392–8396. doi: 10.1073/pnas.90.18.8392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Plowman G. D., Culouscou J. M., Whitney G. S., Green J. M., Carlton G. W., Foy L., Neubauer M. G., Shoyab M. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1746–1750. doi: 10.1073/pnas.90.5.1746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Schmalfeldt B., Kuhn W., Reuning U., Pache L., Dettmar P., Schmitt M., Jänicke F., Höfler H., Graeff H. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res. 1995 Sep 15;55(18):3958–3963. [PubMed] [Google Scholar]
  19. Tamakoshi K., Kikkawa F., Nawa A., Ishikawa H., Mizuno K., Tamakoshi A., Yamagata S., Suganuma N., Tomoda Y. Characterization of extracellular matrix-degrading proteinase and its inhibitor in gynecologic cancer tissues with clinically different metastatic form. Cancer. 1995 Dec 15;76(12):2565–2571. doi: 10.1002/1097-0142(19951215)76:12<2565::aid-cncr2820761224>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  20. Tan M., Yao J., Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 1997 Mar 15;57(6):1199–1205. [PubMed] [Google Scholar]
  21. Yamamoto T., Ikawa S., Akiyama T., Semba K., Nomura N., Miyajima N., Saito T., Toyoshima K. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature. 1986 Jan 16;319(6050):230–234. doi: 10.1038/319230a0. [DOI] [PubMed] [Google Scholar]
  22. Yu D. H., Hung M. C. Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells. Oncogene. 1991 Nov;6(11):1991–1996. [PubMed] [Google Scholar]
  23. Yu D., Wolf J. K., Scanlon M., Price J. E., Hung M. C. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res. 1993 Feb 15;53(4):891–898. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES